Evidence map›Paper›PMID 33539861›Full record

ArticleThe American journal of cardiology2021

Soluble Angiotensin-Converting Enzyme 2, Cardiac Biomarkers, Structure, and Function, and Cardiovascular Events (from the Atherosclerosis Risk in Communities Study).

Aliza Hussain, Olive Tang, Caroline Sun, Xiaoming Jia, Elizabeth Selvin, Vijay Nambi, Aaron Folsom, Gerardo Heiss, Faiez Zannad, Thomas Mosley and 10 more

Open access · greenAbstract readMulticenter Study
In one paragraph

Article in The American journal of cardiology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
1.4field-weighted citation impact, top 18% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 13 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Review
  5. Circulating angiotensin converting enzyme 2 and COVID-19.World journal of clinical cases · 2022
    Review
  6. Article
  7. Role of the renin-angiotensin system in NETosis in the coronavirus disease 2019 (COVID-19).Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie · 2022
    Review
  8. Review
  9. Article
  10. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

20 authors at 10 institutions in 2 countries.

Aliza HussainDepartment of Medicine, Baylor College of Medicine, Houston, Texax; Center for Cardiometabolic Disease Prevention, Baylor College of Medicine, Houston, Texas.
Olive TangDepartment of Epidemiology and Welch Center for Prevention, Epidemiology and Clinical Research, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland.
Caroline SunDepartment of Medicine, Baylor College of Medicine, Houston, Texax.
Xiaoming JiaDepartment of Medicine, Baylor College of Medicine, Houston, Texax.
Elizabeth SelvinDepartment of Epidemiology and Welch Center for Prevention, Epidemiology and Clinical Research, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland.
Vijay NambiDepartment of Medicine, Baylor College of Medicine, Houston, Texax; Center for Cardiometabolic Disease Prevention, Baylor College of Medicine, Houston, Texas; Department of Medicine, Michael E. DeBakey Veterans Affairs Medical Center, Houston, Texas.
Aaron FolsomDivision of Epidemiology and Community Health, University of Minnesota, Minneapolis, Minnesota.
Gerardo HeissDepartment of Epidemiology, University of North Carolina, Chapel Hill, North Carolina.
Faiez ZannadFrench Clinical Research Infrastructure Network Investigation Network Initiative-Cardiovascular and Renal Clinical Trialists, Université de Lorraine, Nancy, France.
Thomas MosleyMemory Impairment and Neurodegenerative Dementia Center, University of Mississippi Medical Center, Jackson, Mississippi.
Salim S ViraniDepartment of Medicine, Baylor College of Medicine, Houston, Texax; Center for Cardiometabolic Disease Prevention, Baylor College of Medicine, Houston, Texas; Department of Medicine, Michael E. DeBakey Veterans Affairs Medical Center, Houston, Texas.
Josef CoreshDepartment of Epidemiology and Welch Center for Prevention, Epidemiology and Clinical Research, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland.
Eric BoerwinkleSchool of Public Health, University of Texas Health Science Center at Houston, Houston, Texas.
Bing YuSchool of Public Health, University of Texas Health Science Center at Houston, Houston, Texas.
Jonathan W CunninghamCardiovascular Division, Brigham and Women's Hospital, and Harvard Medical School, Boston, Massachusetts.
Amil M ShahCardiovascular Division, Brigham and Women's Hospital, and Harvard Medical School, Boston, Massachusetts.
Scott D SolomonCardiovascular Division, Brigham and Women's Hospital, and Harvard Medical School, Boston, Massachusetts.
James A de LemosDivision of Cardiology, University of Texas-Southwestern Medical Center, Dallas, Texas.
Ron C HoogeveenDepartment of Medicine, Baylor College of Medicine, Houston, Texax; Center for Cardiometabolic Disease Prevention, Baylor College of Medicine, Houston, Texas.
Christie M BallantyneDepartment of Medicine, Baylor College of Medicine, Houston, Texax; Center for Cardiometabolic Disease Prevention, Baylor College of Medicine, Houston, Texas. Electronic address: cmb@bcm.edu.
Baylor College of Medicine · USBrigham and Women's Hospital · USJohns Hopkins University · USMichael E. DeBakey VA Medical Center · USThe University of Texas Health Science Center at Houston · USFrench Clinical Research Infrastructure Network · FRThe University of Texas Southwestern Medical Center · USUniversity of Minnesota · USUniversity of Mississippi Medical Center · USUniversity of North Carolina at Chapel Hill · US

Funding

MEDICAL SCIENTIST TRAINING PROGRAMT32GM007309 · NIGMS · JOHNS HOPKINS UNIVERSITY · PI COX, ANDREA L · 1985 to 2019
$43.2M
Medical Scientist Training ProgramT32GM136577 · NIGMS · JOHNS HOPKINS UNIVERSITY · PI ANDREA L COX · 2020 to 2026
$13.4M
Mapping the Progression to HFpEF in the Elderly through Longitudinal Changes in Cardiac FunctionR01HL135008 · NHLBI · UT SOUTHWESTERN MEDICAL CENTER · PI Amil M Shah · 2017 to 2026
$11.5M
Noninvasive Cardiovascular Imaging Research Training ProgramT32HL094301 · NHLBI · BRIGHAM AND WOMEN'S HOSPITAL · PI Marcelo F DI CARLI · 2010 to 2026
$7.8M
Diabetes and Prediabetes in Older Adults in ARICR01DK089174 · NIDDK · JOHNS HOPKINS UNIVERSITY · PI SELVIN, ELIZABETH · 2011 to 2020
$6.4M
Early Detection of Transthyretin Cardiac Amyloidosis: Defining a Novel Target for HFpEF Treatment and Prevention in Late LifeR01HL150342 · NHLBI · BRIGHAM AND WOMEN'S HOSPITAL · PI DORBALA, SHARMILA, SHAH, AMIL M · 2020 to 2023
$4.1M
Quantifying cardiac structure and function to define the progression to hear failure in African AmericansR01HL143224 · NHLBI · UT SOUTHWESTERN MEDICAL CENTER · PI SHAH, AMIL M · 2018 to 2021
$3.4M
Metabolic Signatures Underlying Cardiac Function for Heart Failure in Multi-Ethnic PopulationsR01HL141824 · NHLBI · UNIVERSITY OF TEXAS HLTH SCI CTR HOUSTON · PI YU, BING · 2018 to 2021
$3.1M
Profiling Cardiovascular Events and Biomarkers in the Very Old to Improve Personalized Approaches for the Prevention of Cardiac and Vascular DiseaseR01HL134320 · NHLBI · BAYLOR COLLEGE OF MEDICINE · PI BALLANTYNE, CHRISTIE MITCHELL, SELVIN, ELIZABETH · 2016 to 2019
$3.1M
Trans-omics Analysis to Unravel Molecular Underpinnings of Heart, Lung and Blood Disease Risk FactorsR01HL142003 · NHLBI · UNIVERSITY OF TEXAS HLTH SCI CTR HOUSTON · PI YU, BING · 2018 to 2019
$934k
Research and Mentoring in the Clinical Epidemiology of Type 2 DiabetesK24DK106414 · NIDDK · JOHNS HOPKINS UNIVERSITY · PI SELVIN, ELIZABETH · 2015 to 2019
$654k
Mentoring patient-oriented research in deep phenotyping of cardiac function for heart failure preventionK24HL152008 · NHLBI · UT SOUTHWESTERN MEDICAL CENTER · PI SHAH, AMIL M · 2020 to 2024
$608k
American Heart Association-American Stroke Association 17SDG33661228CSRD VA I01 CX001112NHLBI NIH HHS HHSN268201700001CNHLBI NIH HHS HHSN268201700001INHLBI NIH HHS HHSN268201700002CNHLBI NIH HHS HHSN268201700002INHLBI NIH HHS HHSN268201700003CNHLBI NIH HHS HHSN268201700003INHLBI NIH HHS HHSN268201700004CNHLBI NIH HHS HHSN268201700004INHLBI NIH HHS HHSN268201700005CNHLBI NIH HHS HHSN268201700005INHLBI NIH HHS K24 HL152008NHLBI NIH HHS R01 HL134320NHLBI NIH HHS R01 HL135008NHLBI NIH HHS R01 HL141824NHLBI NIH HHS R01 HL142003NHLBI NIH HHS R01 HL143224NHLBI NIH HHS R01 HL150342NHLBI NIH HHS T32 HL094301NIDDK NIH HHS F30 DK120160NIDDK NIH HHS K24 DK106414NIDDK NIH HHS R01 DK089174NIGMS NIH HHS T32 GM007309NIGMS NIH HHS T32 GM136577
6 · The paper itself

Abstract

Membrane-bound angiotensin-converting enzyme 2 is important in regulation of the renin-angiotensin-aldosterone system, but the association of cleaved soluble ACE2 (sACE2) with cardiovascular disease (CVD) is unclear. We evaluated the association of sACE2 with cardiac biomarkers, structure, and function and cardiovascular events in the Atherosclerosis Risk in Communities Study. sACE2 was measured in a subset of 497 participants (mean age 78±5.4 years, 53% men, 27% black); Cox regression analyses assessed prospective associations of sACE2 with time to first CVD event at median 6.1-year follow-up. sACE2 was higher in men, blacks, and participants with prevalent CVD, diabetes, or hypertension. Higher sACE2 levels were associated with significantly higher biomarkers of cardiac injury (high-sensitivity cardiac troponin I and T, N-terminal pro-B-type natriuretic peptide), greater left ventricular mass index, and impaired diastolic function in linear regression analyses, and with increased risk for heart failure hospitalization (adjusted hazard ratio per natural log unit increase [HR] 1.32, 95% confidence interval [CI] 1.10 to 1.58), CVD events (HR 1.34, 95% CI 1.13 to 1.60), and all-cause death (HR 1.26, 95% CI 1.01 to 1.57). In an elderly biracial cohort, sACE2 was positively associated with biomarkers reflecting myocardial injury and neurohormonal activation, left ventricular mass index, impaired diastolic function, CVD, events and all-cause death.

Indexed as

AgedAngiotensin-Converting Enzyme 2AtherosclerosisBiomarkersFemaleFollow-Up StudiesHeart VentriclesHumansMaleMiddle AgedRenin-Angiotensin SystemRisk FactorsTime FactorsVentricular Function, LeftAngiotensin-Converting Enzyme 2Biomarkers

Identifiers

PMID33539861
PMCPMC8038970
OpenAlexW3126947385

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.